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wk4) and all patients IFRT (20-30 Gy) post AutoSCT. Three
patients did not proceed onto RI AlloSCT (1 HD parental with-
drawal, 1 Burkitts PD, and 1 Burkitts too early post autoSCT) 9/12
proceeded to RI AlloSCT.. RI: Fludarabine 30 mg/m2  5d,
Busulfan 3.2 mg/kg  2d, and R ATG 2 mg/kg  4d (UCB
recipients)  AlloSCT (1 related 6/6 PBSC, 1 related 5/6 PBSC, 1
8/10 MUD, 1 5/6 UCB, 5 4/6 UCB). GVHD prophylaxis: tacroli-
mus (0.03 mg/kg CIVI) on day-1- 60 and MMF (15 mg/kg
IV/PO q12h) day 1 &luAmn;28 as previously reported (Os-
unkwo/Cairo et al BBMT 2004). Six HD (3 stage IIA, 1 stage IIB,
1 stage IIIB, 1 stage IVB) and 3 NHL ( ALCL n 1, lymphoblastic
n  1, DLBCL n  1, ) have been treated. MA AutoSCT  RI
AlloSCT were well tolerated in all patients. Median time to RI
AlloSCT after MA AutoSCT was 130 days. Median F/U is 924
days. Toxicity: grade 3 hematuria (n  1), grade 3/4 infection
without neutropenia (n  4), grade 4 infection with neutropenia
(n  2), grade 4 pulmonary ﬁbrosis (n  1), grade 4 hearing loss
(n  1), and grade 4 thrombocytopenia (n  1), grade 4 neuro-
toxicity (n  1). All patients achieved 100% donor chimerism.
GVHD: grade II-III aGVHD (2/8), cGVHD (3/8). Four of 6 HD
patients: are NED; 2 patients died; PD n  1 and cGVHD n  1.
Two of 3 NHL: are NED, 1 died of PD. There has been one death
(NRM) from infection day 632. The estimated OS at 1 year is
56.2%. In summary, MA AutoSCT followed by IFRT, targeted
monoclonal antibody therapy, and RI AlloSCT is feasible and well
tolerated in pediatric patients with relapsed HD/NHL. A larger
controlled study with longer follow up is required to determine if
this approach will reduce relapse, MDS, long-term toxicity, and
improve EFS.
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BORTEZOMIB PRIOR TO AUTOLOGOUS TRANSPLANT IN MULTIPLE
MYELOMA: EFFECTS ON MOBILIZATION, ENGRAFTMENT, AND MARK-
ERS OF IMMUNE FUNCTION
Uy, G.L.1, Peles, S.1, Fisher, N.M.1, Tomasson, M.H.1, DiPersio, J.F.1,
Vij, R.1 Washington University School of Medicine, St. Louis, MO.
To explore the potential role of bortezomib (VELCADE®) in
the frontline treatment of multiple myeloma, we conducted a study
of bortezomib administered prior to autologous transplant. The
primary objective was to determine the effects of bortezomib on
cytokine based mobilization and engraftment. Given the critical
role NF-B in lymphocyte development and survival, we also
sought to determine the effects of bortezomib on markers of
immune function. Following induction, two cycles of bortezomib
1.3 mg/m2 were administered on days 1, 4, 8, and 11 of a 21-day
treatment cycle. Peripheral blood stem cells were mobilized with
G-CSF 10 mcg/kg/day for 5 days and harvested by large volume
apheresis (20 L/day) until a minimum of 2.5  106 CD34
cells/kg were collected. High-dose melphalan 200 mg/m2 was
administered followed by autologous stem cell transplant with
GM-CSF 250 mcg/m2/day support until neutrophil engraftment.
Peripheral blood was collected at baseline (cycle 1, day 1) and after
treatment with bortezomib (cycle 2, day 18) for analysis of lym-
phocyte subsets and serum cytokines. Forty patients were enrolled
with 37 continuing on to autologous transplant. Prior to receiving
bortezomib, 20 patients had been previously treated with an an-
thracycline, 22 with thalidomide, and two patients had no induc-
tion therapy. Stem cell collection was successful in 37 of 38 patients
(97%) with the median ﬁrst collection of 4.24  106 CD34cells/
kg. Following transplant, all patients engrafted with a median time
to neutrophil engraftment (ANC  500/mm3) of 11 days (range
9-14 days) and platelet engraftment (platelet count 20,000/mm3)
of 11 days (range 9-31 days). In an intention-to-treat analysis at
100 days post-transplant, we observed a CR in 6 patients (15%), a
near CR in 10 patients (25%) and a PR in an additional 19 patients
(48%) for an overall response rate of 88%. Following treatment
with bortezomib, we observed a 38% decrease in CD56 NK cells
(P  .02) and a 26% increase in CD4/CD8 ratio (P  .0006) with
a 18% decrease in CD8 cytotoxic T-cells (P  .054). No signif-
icant changes were detected in either Th1 or Th2 serum cytokine
levels: IL-2 (P  .116), TNF-alpha (P  .854), IFN- (P  .070),
IL-4 (P  .240), IL-6 (0.236), IL-10 (0.151). We conclude that
pretransplant bortezomib does not adversely impair stem cell mo-
bilization or engraftment. Bortezomib also decreases NK and cy-
totoxic T cell subsets without measurable change in serum Th1
and Th2 cytokines.
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IMMUNOTHERAPY WITH RITUXIMAB/INTERLEUKIN 2 (IL-2) FOLLOW-
ING AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANT
(ASCT) AS TREATMENT FOR CD20 POSITIVE NON-HODGKIN’S LYM-
PHOMA
Holmberg, L.A.1,2,3, Maloney, D.1,2,3, Gooley, T.1,2, Bensinger,
W.I.1,2,3 1. Fred Hutchinson Cancer Research Center, Seattle, WA; 2.
University of Washington School of Medicine, Seattle, WA; 3. Puget
Sound Oncology Consortium, Seattle, WA.
Relapse of NHL remains a problem after ASCT. Early after
ASCT, the immune system is not very active and the addition of
immunotherapy may decrease the incidence of relapse and prolong
survival. In an initial phase I/II trial at our center, the immune-
modulator IL-2 increased NK and LAK activity in vitro. Since
Rituximab can lyse CD20 cells by ADCC, adding Rituximab to
IL-2 should boost its effectiveness. From January 2000, 20 patients
with CD20 NHL received ASCT followed by Rituximab/IL-2
therapy. The pathology at the time of ASCT included: follicular
small/large cleaved (n  2), diffuse large/T cell rich B cell (n  8),
mantle cell (n  4) and transformed from indolent to diffuse (n 
6). The disease status was primary refractory (n 3), relapse 1(PR)
(n  5), remission 1 (n  3), remission 2 (n  8) and relapse
2/refractory (n  1). The median age of the patients was 46 years
(range 31-70). The median time to initiation of the therapy was 79
days after transplant (range 49-100). The treatment schema was:
IL-2 0.6 106 IU/m2/day sc times 12 weeks, followed by 1.4 106
IU/m2 sc three times/week for an additional 12 weeks (for a total
of 24 weeks of IL-2 therapy). Rituximab was given iv at 375 mg/m2
for a total of 4 doses: beginning one day prior to starting IL-2, then
between days 25-30, 50-55 and 75-80 post beginning IL-2. NCI
Common Toxicity Criteria were used to evaluate adverse events.
Most common grade 3 /4 toxicities were neutropenia (n  9),
pneumonia (n  2), hypothyroidism (n  1), hypokalemia (n  1)
and pulmonary dysfunction (decreased DLCO) (n  1). Neutro-
penia responded to G-CSF. There were 11 infectious episodes,
pneumonia (inﬂuenza n  1) and pneumococcus strept (n  1),
oral thrush (n  2), herpes simplex (n  1), urinary tract infection
(n  1), zoster (n  1) and upper respiratory infection (n  4).
Most common side effects were fatigue, ertyheyma/indurationa/
discomfort at IL-2 injection sites and ﬂu-like symptoms. Seven
patients stopped therapy before completing 24 weeks due to sub-
dural hematoma and progression of NHL (n 1), pneumonia (n
2), decreased DLCO (n  1) and at own or physician’s choice
without grade 3/4 toxicity (n  3) at 9, 13, 14.5 weeks. With a
median follow-up of 45 months (range 14-64), 18 patients remain
alive and in compete remission. The combination of IL-2/ Ritux-
imab can be administered with acceptable toxicity and has a high
response rate. A randomized trial has been initiated to address
whether this combination therapy is beneﬁcial to patients.
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HIGH RATES OF REACTIVATION OF VARICELLA ZOSTER VIRUS (VZV)
ASSOCIATED WITH BORTEZOMIB (VELCADE) WHEN GIVEN PRE AND
POST HIGH DOSE CHEMOTHERAPY (HDCT)
Peles, S.1, Uy, G.L.1, Fisher, N.M.1, Tomasson, M.H.1, DiPersio, J.F.1,
Vij, R.1 Washington University School of Medicine, St. Louis, MO.
We evaluated the tolerability and efﬁcacy of the proteasome
inhibitor bortezomib administered to multiple myeloma (MM)
patients both prior to, and as consolidation therapy following
HDCT, in a prospective pilot study. Patients received 2 cycles of
bortezomib 1.3 mg/m2 on days 1, 4, 8, and 11 of every 21 days,
prior to stem cell collection and melphalan 200mg/m2, followed by
six cycles of consolidation bortezomib 1.3 mg/m2 given once
weekly for 4 of every 5 weeks, 90–120 days following transplanta-
tion. Of 40 enrolled patients, 33 have received at least one post
transplantation cycle of consolidation bortezomib. Patient and
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disease characteristics at diagnosis were as follows (no. of patients):
male (22), female (11), median age 56 years (range 39–70), Stage II
(9), Stage III (24), IgG (22), IgA (9), free light chain (2). Median
paraprotein at initiation of consolidation was 0 (range 0–3.6) (n 
33), day 1 cycle 4 was 0.1 (range 0–2.1) (n  23), and at end of
study was 0.35 (range 0–3.4) (n  20). With a median follow up of
14 months, disease progression has occurred in 5 patients with 1
death. Fourteen patients (42%) experienced reactivation of VZV, 2
patients had human herpes virus 6 reactivation, and 1 patient had
oral herpes simplex virus reactivation, all requiring therapy. The
median absolute lymphocyte count at the onset of viral reactivation
was 1336/mcl (range  600–4800/mcl). A signiﬁcant difference
was seen in the mean CD8 count just prior to transplantation
between those patients with viral reactivation (243, range 77–685)
and the rest of the study population (392, range 87–1339) (P 
.03). The median time from enrollment to VZV reactivation was
189 days (range 25–375). Ten patients had grade 1/2 and none had
grade 3/4 neuropathy at study enrollment. At initiation of post
transplant bortezomib 21 (64%) had grade 1/2 neuropathy and 1
(3%) had grade 3/4 neuropathy. Treatment emergent neuropathy
on once weekly bortezomib was seen in only 3 patients (9%),
necessitating dose reduction (1 patient) or discontinuation of ther-
apy (2 patients). No grade 3/4 thrombocytopenia or neutropenia
was observed with consolidation bortezomib. We conclude that
bortezomib when administered pre- and post HDCT in MM
patients results in a very high rate of viral reactivation. This ﬁnding
may be explained by a decrease in circulating CD8 T cells and has
implications for future clinical trials of bortezomib in this setting.
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SALVAGE NON-MYELOABLATIVE ALLOGENEIC TRANSPLANTATION AF-
TER FAILURE OF AN AUTOLOGOUS TRANSPLANTATION IN MULTIPLE
MYELOMA
Qazilbash, M.H.1, Saliba, R.1, Mendoza, F.1, Roden, L.1, Hosing, C.1,
Couriel, D.E.1, Kebriaei, P.1, Popat, U.1, De Lima, M.1,
Champlin, R.E.1, Giralt, S.A.1 University of Texas-M. D. Anderson
Cancer Center, Houston, TX.
Introduction: Salvage therapy for patients relapsing after an
autologous stem cell transplant for multiple myeloma is not well
deﬁned. Allogeneic stem cell transplantation with a reduced-
intensity preparative regimen has been one of the approaches
used in this setting. We analyzed the outcomes of 30 patients
who underwent a reduced-intensity allogeneic transplant after
disease progression from the ﬁrst autologous transplant. Meth-
ods: Median age was 51 years (range 32–65). Twenty-two
patients underwent transplants from a related donor (21 HLA-
identical, 1 with a single class 1 antigen mismatch), while 8 from
an unrelated donor (7 HLA-identical, one with a single DQ
mismatch). Preparative regimen in 28/30 patients was a combi-
nation of ﬂudarabine 30 mg/m2  4 days and melphalan 70
mg/m2 IV  2 days (24 patients), while 2 patients received
ﬂudarabine 25 mg/m2 IV  5d and cyclophosphamide 1g/m2
IV  3d. Patients undergoing unrelated donor transplants also
received the rabbit ATG. Tacrolimus and methotrexate were
used for GVHD prophylaxis. The median interval between the
ﬁrst and the second transplant was 18 months. Seventeen pa-
tients had resistant and progressive disease. These patients had
received a median of 5 chemotherapy regimens prior to trans-
plant. In 21/30 patients with available cytogenetic studies, 14
were normal and 7 abnormal. Results: Twenty-one of the 30
patients (70%) achieved a complete (8) or partial response (13).
With a median follow up of 19 months (4–75), 1-year progres-
sion-free survival (PFS) was 24% and 1-year overall survival
(OS) was 59%. Median PFS and OS were 7 and 16 months,
respectively. One-year non-relapse mortality was 17%. Acute
grade II/IV GVHD was seen in 9/30 (30%) and chronic GVHD
in 13/30 (43%: limited 16%, extensive 27%) patients. Disease
progression remained the major cause of failure with 14 (46%)
dying of progressive disease. On univariate analysis, an interval
of 1 year between two transplants was a predictor of early
progression (P  .02) and the presence of progressive/ resistant
disease showed a trend towards shorter overall survival (P 
.07). Conclusions: Salvage allogeneic transplantation can
achieve responses in 70% of heavily pretreated patients, with
acceptable toxicity and durable remissions in patients treated
more than a year after a prior autograft. Patients with chemo-
sensitive disease seem to have a longer overall survival.
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SECOND AUTOLOGOUS STEM CELL TRANSPLANTATION AS SALVAGE
THERAPY IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA: IM-
PROVED OUTCOMES IN PATIENTS WITH LONGER DISEASE FREE IN-
TERVAL AFTER FIRST AUTOLOGOUS STEM CELL TRANSPLANTATION
Mikhael, J.1, Samiee, S.1, Stewart, A.K.2, Chen, C.1, Trudel, S.1,
Franke, N.1, Winter, A.1, Phillips, D.1, Reece, D.1 1. Princess Margaret
Hospital, Toronto, ON, Canada; 2. Mayo Clinic, Scottsdale, AZ.
Background: Single autologous stem cell transplant (ASCT) is
considered the standard of care for younger multiple myeloma
(MM) patients (pts). However, it is not curative and virtually all
patients will ultimately relapse. The role of a second ASCT as
salvage therapy is unclear. Methods: Retrospective review of all
MM pts who received a second ASCT as salvage therapy at Prin-
cess Margaret Hospital. Results: Between March 1992 and Sep-
tember 2005, 40 MM pts received a second ASCT for relapsed
MM at our institution. Median age was 58 years (range 39–69) at
second transplant. Twenty-one pts were male. Immunoglobulin
subtype included IgG (25), IgA (9), light chain (3), nonsecretory
(2), and IgM(1). Median initial albumin was 42g/l (27–49). In 20
patients in whom cytogenetic studies were available, 3 were posi-
tive for the 13q deletion. Transplant conditioning regimen for ﬁrst
transplant was melphalan (MEL)  TBI  etoposide (E) in 6,
MEL alone in 27, and other regimens in 7 pts. Second ASCT
conditioning consisted of MEL  TBI  E in 2, MEL alone in 37
and BU  CY in 1. Median CD34 counts were 10.96  106/L and
4.85  106/L for ﬁrst and second ASCT, respectively. The median
time from diagnosis to ﬁrst transplant was 9 months (2–74). The
median time to relapse after the ﬁrst transplant was 29 months
(6–85), with a median interval between transplants of 39 months
(6–99). The median time to progression after the second transplant
was 14 months (5–56). One transplant-related death occurred. At
median follow-up after second ASCT of 19 months (1–74), 29
(73%) pts are alive. Nineteen (48% of all pts) are free of disease
progression. The median progression-free survival (PFS) was 18
months and median overall survival (OS) was 41 months after
second ASCT. Long term progression-free status based on the
progression-free interval after ﬁrst transplant is summarized in
(Table1). Conclusions: (1) Second ASCT is a feasible and safe
salvage therapy in relapsed MM patients; (2) second ASCT is
effective in providing median progression-free survival of 18
months and median overall survival of 41 months after second
ASCT; (3) the longer the disease free interval after ﬁrst ASCT the
more effective second ASCT is at extending both progression-free
survival and overall survival.
Table 1. Survival Based on Time to Relapse After 1st ASCT
Interval from
1st ASCT to
Relapse
Number of
Patients
Median Progression
Free Survival after
2nd ASCT
2 Year Overall
Survival After
2nd ASCT
< 24 months 13 17 months 32%
24–36
months 13 29 months 60%
> 36 months 14 54 months 88%
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MCVAC REGIMEN IN AUTOLOGOUS PERIPHERAL BLOOD STEM CELL
TRANSPLANTATION FOR HIGH-RISK DIFFUSE LARGE B CELL LYM-
PHOMA (DLBCL)
Kato, J.1, Yokoyama, K.1, Mori, T.1, Tsukada, Y.1, Chen, C.-K.1,
Ikeda, Y.1, Okamoto, S.-I.1 Division of Hematology, Department of
Medicine, Keio University School of Medicine, Tokyo, Japan.
Background: High dose chemotherapy followed by autolo-
gous stem cell transplantation in high-risk or relapsed aggres-
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